摘要
目的探讨阿德福韦酯联合胸腺肽α1治疗慢型乙型肝炎的临床疗效。方法将64例慢性乙肝患者随机分为联合治疗组和对照组,各32例。对照组予阿德福韦酯胶囊10 mg/d口服,连续治疗72周;联合治疗组在对照组基础上,于治疗过程中前24周同时加用胸腺肽α1注射液皮下注射,1.6 mg/次,每周2次。2组于治疗前后分别测定ALT、AST、TBIL指标,观察治疗前后肝功能改善情况;每24周测定HbeAg/HbeAb及HBV-DNA(定量)水平,观察HbeAg/HbeAb血清转换率及HBV-DNA转阴率变化情况。结果 2组治疗前后在肝功能指标改善和HBV-DNA转阴率方面无显著性差异(P>0.05),联合治疗组HbeAg/HbeAb血清转换率明显高于对照组(P<0.05)。结论阿德福韦酯联合胸腺肽α1治疗慢性乙型肝炎在HbeAg/HbeAb血清转换率方面明显优于单用阿德福韦酯。
Objective To explore the clinical effect of Adefovir Dipivoxil combined with Thymosin α1 on chronic hepatitis B.Methods Sixty-four patients with chronic hepatitis B were randomly divided into combined treatment group（n=32） and control group（n=32）.Patients in control group were only given Adefovir Dipivoxil 10mg/d for 72 weeks,while in combined treatment group,Thymosin was added α1 by the way of subcutaneous injection 1.6 mg twice per week during the first 24 weeks on the basis of control group.The levels of ALT,AST and TBIL were detected before and after treatment.HbeAg/HbeAb seroconversion and HBV-DNA negative conversion rates were observed every 24 weeks.Results No significant differences were found in liver function improvement and HBV-DNA negative conversion rates between two groups.However,the HbeAg/HbeAb seroconversion rates in combined treatment group were significantly higher than those in control group（P0.05）.Conclusion The clinical effect of Adefovir Dipivoxil combined with Thymosin α1 are significantly better than Adefovir Dipivoxil only on HbeAg/HbeAb seroconversion in the treatment of chronic hepatitis B.
出处
《实用临床医药杂志》
CAS
2011年第13期77-78,83,共3页
Journal of Clinical Medicine in Practice
